Kiromic Biopharma Inc
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-s… Read more
Kiromic Biopharma Inc (KRBP) - Net Assets
Latest net assets as of December 2024: $-12.59 Million USD
Based on the latest financial reports, Kiromic Biopharma Inc (KRBP) has net assets worth $-12.59 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.54 Million) and total liabilities ($21.13 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-12.59 Million |
| % of Total Assets | -147.3% |
| Annual Growth Rate | N/A |
| 5-Year Change | -210.78% |
| 10-Year Change | N/A |
| Growth Volatility | 296.6 |
Kiromic Biopharma Inc - Net Assets Trend (2018–2024)
This chart illustrates how Kiromic Biopharma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Kiromic Biopharma Inc (2018–2024)
The table below shows the annual net assets of Kiromic Biopharma Inc from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-12.59 Million | -38.00% |
| 2023-12-31 | $-9.12 Million | -57.94% |
| 2022-12-31 | $-5.77 Million | -121.14% |
| 2021-12-31 | $27.32 Million | +140.45% |
| 2020-12-31 | $11.36 Million | +474.13% |
| 2019-12-31 | $1.98 Million | +645.95% |
| 2018-12-31 | $265.30K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kiromic Biopharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13109530000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | % |
| Other Components | $137.21 Million | % |
| Total Equity | $-12.59 Million | 100.00% |
Kiromic Biopharma Inc Competitors by Market Cap
The table below lists competitors of Kiromic Biopharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
INFORMATION SVC GRP
BE:ZZG
|
$47.66K |
|
CARLYLE COMMODIT.CORP.
F:BJ4
|
$47.66K |
|
ProbeLeader Co., Ltd.
TWO:5246
|
$47.67K |
|
SABA CA.INC+OP.NEW DL-01
F:14H0
|
$47.70K |
|
MPC CAPITAL
BE:MPCK
|
$47.64K |
|
Halloren Schokoladenfabrik Aktiengesellschaft
HM:H2RB
|
$47.63K |
|
BGD
WAR:BGD
|
$47.60K |
|
ALOS3F
SA:ALOS3F
|
$47.60K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kiromic Biopharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -9,120,800 to -12,587,000, a change of -3,466,200.
- Net loss of 26,898,000 reduced equity.
- Other comprehensive income increased equity by 2.
- Other factors increased equity by 23,431,798.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.90 Million | -213.7% |
| Other Comprehensive Income | $2.00 | +0.0% |
| Other Changes | $23.43 Million | +186.16% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Kiromic Biopharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $0.08 | $0.04 | x |
| 2019-12-31 | $0.51 | $0.04 | x |
| 2020-12-31 | $1.56 | $0.04 | x |
| 2021-12-31 | $2.39 | $0.04 | x |
| 2022-12-31 | $-0.35 | $0.04 | x |
| 2023-12-31 | $-0.28 | $0.04 | x |
| 2024-12-31 | $-0.48 | $0.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kiromic Biopharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-270.10%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -1438.26% | 0.00% | 0.00x | 3.30x | $-3.84 Million |
| 2019 | -189.51% | 0.00% | 0.00x | 1.34x | $-3.95 Million |
| 2020 | -169.01% | 0.00% | 0.00x | 1.13x | $-20.34 Million |
| 2021 | -93.90% | 0.00% | 0.00x | 1.12x | $-28.39 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-37.60 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-20.38 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-25.64 Million |
Industry Comparison
This section compares Kiromic Biopharma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kiromic Biopharma Inc (KRBP) | $-12.59 Million | -1438.26% | N/A | $47.64K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |